Pages that link to "Q44472519"

The following pages link to Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial (Q44472519):

Displaying 32 items.

• Lost in translation: endoplasmic reticulum stress and the decline of β-cell health in diabetes mellitus (Q26864403) (← links)
• Emerging gliptins for type 2 diabetes (Q34347884) (← links)
• Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial (Q34813843) (← links)
• The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis (Q36301818) (← links)
• Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes (Q36972891) (← links)
• Alternative Agents in Type 1 Diabetes in Addition to Insulin Therapy: Metformin, Alpha-Glucosidase Inhibitors, Pioglitazone, GLP-1 Agonists, DPP-IV Inhibitors, and SGLT-2 Inhibitors (Q38259869) (← links)
• Combination immunotherapies for type 1 diabetes mellitus (Q38358009) (← links)
• Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus (Q38770952) (← links)
• Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus (Q38916838) (← links)
• Differentiation of Diabetes by Pathophysiology, Natural History, and Prognosis. (Q39040207) (← links)
• Preliminary study characterizing the use of sitagliptin for glycemic control in healthy Beagle dogs with normal gluco-homeostasis (Q39175579) (← links)
• Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus (Q39300071) (← links)
• Moving beyond subcutaneous insulin: the application of adjunctive therapies to the treatment of type 1 diabetes. (Q42008289) (← links)
• Medical Nutrition Therapy in Type 1 Diabetes Mellitus (Q42370530) (← links)
• Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S). (Q42371744) (← links)
• Meta-genome-wide association studies identify a locus on chromosome 1 and multiple variants in the MHC region for serum C-peptide in type 1 diabetes (Q50060749) (← links)
• Difference in glucagon-like peptide-1 concentrations between C-peptide negative type 1 diabetes mellitus patients and healthy controls. (Q51319337) (← links)
• Use of Sitagliptin With Closed-Loop Technology to Decrease Postprandial Blood Glucose in Type 1 Diabetes. (Q53396068) (← links)
• Type 2 treatments for type 1 diabetes. (Q53751922) (← links)
• DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. (Q55048866) (← links)
• Adjunctive therapy for glucose control in patients with type 1 diabetes. (Q55234623) (← links)
• Understanding of type 1 diabetes mellitus: What we know and where we go (Q57297964) (← links)
• Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study (Q59624365) (← links)
• Incretin-based therapies for patients with type 1 diabetes: a meta-analysis (Q64253654) (← links)
• Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus (Q64780233) (← links)
• The new insights from DPP-4 inhibitors: their potential immune modulatory function in autoimmune diabetes (Q87135143) (← links)
• Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: A 1-year pilot study (Q89643200) (← links)
• Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions (Q89729129) (← links)
• Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes (Q90324457) (← links)
• Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes (Q91778233) (← links)
• Exercise and the dipeptidyl-peptidase IV inhibitor sitagliptin do not improve beta-cell function and glucose homeostasis in long-lasting type 1 diabetes-A randomised open-label study (Q91787185) (← links)
• Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program (Q92126784) (← links)